AstraZeneca's AZD0120 is positioned in the emerging CAR T-cell therapy market, targeting autoimmune diseases such as systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis. The dual targeting mechanism may provide a competitive edge over existing therapies, particularly in indications with high unmet needs. The trial's multi-cohort design allows for the exploration of efficacy across different autoimmune conditions, potentially expanding the market reach. Given the increasing prevalence of autoimmune diseases and the limitations of current treatments, successful outcomes could lead to significant commercial opportunities. However, the presence of established competitors in the CAR T-cell space necessitates careful monitoring of trial results and market dynamics.